Table 2. Cox regression analysis for PFS... | American Society of Hematology

Table 2.

Cox regression analysis for PFS in ibrutinib-treated CLL cohort (whole cohort, n = 158)

Factor	Univariable analysis			Multivariable analysis*
Factor	HR	95% CI	P	HR	95% CI	P
CD49d⁺†	3.03	1.34-6.87	.0079	2.63	1.13-6.10	.0242
UM IGHV	1.71	0.75-3.88	.199	—	—	—
TP53 disruption	2.63	1.37-5.06	.0038	2.10	1.06-4.14	.0327
Rai stage III-IV	2.43	1.31-4.49	.0046	n.i.	n.i.	n.i.
Lines of therapy >1‡	4.49	2.39-8.45	<.0001	4.80	2.54-9.08	<.0001

Factor	Univariable analysis			Multivariable analysis*
Factor	HR	95% CI	P	HR	95% CI	P
CD49d⁺†	3.03	1.34-6.87	.0079	2.63	1.13-6.10	.0242
UM IGHV	1.71	0.75-3.88	.199	—	—	—
TP53 disruption	2.63	1.37-5.06	.0038	2.10	1.06-4.14	.0327
Rai stage III-IV	2.43	1.31-4.49	.0046	n.i.	n.i.	n.i.
Lines of therapy >1‡	4.49	2.39-8.45	<.0001	4.80	2.54-9.08	<.0001

All factors with a significant P value in univariable analyses were entered in the multivariable analysis.

CD49d⁺ cases were obtained by combining cases with ≥30% homogeneous CD49d expression and cases with CD49d bimodal expression.

Comparison between 0 and 1 vs >1 lines of therapy.